-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Recent News from ILCN
-
ARROS-1 Findings Reinforce Potential of Zidesamtinib in Pretreated ROS1-Altered NSCLC
The highly ROS1-selective TKI showed durable responses in previously treated patients with ROS1-altered NSCLC, according to data presented by Dr. Alexander E. Drilon.
-
Aumolertinib Plus Chemo Shows Modest PFS Gain Over Monotherapy for EGFR/TSG-Mutant NSCLC
Investigator Dr. Jie Wang presented results from the first-of-its-kind trial comparing combination therapy with monotherapy in this patient population.
-
Perioperative Nivolumab Proves Safe, Effective for Patients with Resectable Early-Stage NSCLC
Dr. Jonathan Spicer shared patient-reported outcomes data from CheckMate 77T showing the regimen is both safe and tolerable for patients.
-
Step Into the IASLC’s New Digital Community
Introducing Thoracic Circle: a global hub for thoracic oncology experts to share, collaborate, and connect like never before.
-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
Dr. Mariano Provencio said the results could potentially define a standard adjuvant treatment for patients with resectable ES-NSCLC; however, longer-term observation is needed.
-
COMPEL Data Show Osimertinib Plus Chemo Beats Chemo Alone for EGFRm NSCLC Following Progression
While ultimately underpowered, Dr. Giulia Pasello said combination therapy demonstrated an improvement in median PFS compared to chemotherapy alone.
-
Choosing Wisely: Strategies for Navigating Therapeutic Options in Special SCLC Populations
Motoko Tachihara, MD, PhD, addresses various treatment strategies for SCLC populations in an interview with ILCN.
-
The Role of Physiotherapy in Enhancing Lung Cancer Patients’ Quality of Life
Leading experts will outline how genomics, AI, and surgical technology are shaping the next generation of thoracic oncology.
-
Scientific Plenary to Spotlight Innovation and Empowering Future Oncologists
During the session, Drs. Arsela Prelaj, Victor Velculescu, and Lars Konge will address topics that promise to shape the future of thoracic oncology.
-
Test Your Knowledge at the Closing Lunch of the 2025 World Conference on Lung Cancer
Before you depart Barcelona, join your colleagues for lunch and an entertaining trivia competition, hosted by quizmaster Stephen Liu, MD.